Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates
Provided By GlobeNewswire
Last update: May 15, 2025
- Duchenne (SGT-003): Participant dosing ongoing in the Phase 1/2 INSPIRE DUCHENNE trial; Solid on track to discuss accelerated pathways with U.S. FDA later in 2025 -
Read more at globenewswire.com
